Tasocitinib

被引：24

作者：

不详

机构：

来源：

Drugs in R & D | 2010年 / 10卷 / 4期

关键词：

Crohns-disease; Treatment; Dry-eyes; Inflammatory-bowel-diseases; Janus-kinase-3-inhibitors; Psoriasis; Psoriatic-arthritis; Research-and-development; Rheumatoid-arthritis; Spondylitis; Tasocitinib; therapeutic use; Transplant-; rejection;

D O I：

10.2165/11588080-000000000-00000

中图分类号：

学科分类号：

摘要：

Tasocitinib (CP-690,550; CP-690550; CP690550), an orally active immunosuppressant, is being developed by Pfizer for the treatment of rheumatoid arthritis, inflammatory bowel disease, dry eyes, ankylosing spondylitis, psoriasis, psoriatic arthritis, and for the prevention of transplant rejection. Tasocitinib specifically inhibits Janus activated kinase 3 (JAK3), which has a pivotal role in cytokine signal transduction that governs lymphocyte survival, proliferation, differentiation, and apoptosis. This review discusses the key development milestones and therapeutic trials of this drug. © 2010 Adis Data Information BV. All rights reserved.

引用

页码：271 / 284

页数：13

共 25 条

[1]

Oral. Tasocitinib Demonstrates Statistically Significant Response by 12 Weeks in Phase 2 Study of People with Moderate to Severe Plaque Psoriasis, (2010)

[2]

Potential New Pfizer Medicine Reduces Transplant Rejection Rates in Animal Studies, Without Side Effects of Current Therapies, (2003)

[3]

First Phase 3 Trial, Tasocitinib (CP-690, 550), an Oral. JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function, (2010)

[4]

New Pfizer Pipeline Shows Progress and Growth in Vaccines, Biologics and High-priority Disease Areas, (2010)

[5]

Pfizer Development Pipeline Shows Advances in High-priority Disease Areas, (2009)

[6]

Cohen S., Zwillich S.H., Chow V., Et al., Co-administration of the JAK inhibitor CP-690, 550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment, British Journal of Clinical Pharmacology, 69, 2, pp. 143-151, (2010)

[7]

Harness J., Clucas A., Krueger J., Et al., Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effects of CP-690, 550 in subjects with psoriasis, 67th Annual Meeting of the American Academy of Dermatology, (2009)

[8]

CP-690, 550, Pfizer's Oral. JAK Inhibitor, Demonstrates Response Both Alone and in Combination with Methotrexate at 24 Weeks in Patients with Active Rheumatoid Arthritis, (2009)

[9]

Kanik K., Fleischmann R., Cutolo M., Et al., Phase 2B dose ranging monotherapy study of the oral JAK inhibitor CP-690, 550 or adalimumab vs placebo in patients with active rheumatoid arthritis with an inadequate response to DMARDs, 10th Annual Congress of the European League Against Rheumatism, (2009)

[10]

Kremer J., Cohen S., Wilkinson B., Et al., The oral Jak inhibitor CP-690, 550 in combination with methotrexate is efficacious, safe and well tolerated in patients with active rheumatoid arthritis with an inadequate response to methotrexate alone, 72nd Annual Scientific Meeting of the American College of Rheumatology and the 43rd Annual Meeting of the Association of Rheumatology Health Professionals (Late Breaking Abstr.), (2008)

← 1 2 3 →